BioSpace News Archive

Drug development is a Sisyphean endeavor that takes over 10 years of work, and costs over $2.6B to bring a single drug to the market.

Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30 pm PT / 7:30 pm ET.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2022 achievements and outlining the Company’s key business objectives for 2023.

Mammoth Biosciences, Inc. today announced its participation in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Egnyte, the secure platform for content collaboration and governance, recently announced it will be providing early-stage life sciences innovators complimentary access to their award-winning Egnyte for Life Sciences platform

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”) announced today the appointments of three new independent board members, bringing the total board membership to seven.

A research team led by Hospital for Special Surgery Research Institute, in collaboration with Weill Cornell Medicine, has been awarded two grants, one from the Department of Defense and one from the National Institutes of Health, to conduct groundbreaking research regarding lupus flares.1 Sun exposure can trigger skin lesions and worsening of kidneys or other internal organs affected by lupus, but how inflammation at the skin leads to internal organ effects is unknown.

eFFECTOR Therapeutics, Inc. provided an update on its ongoing clinical development programs for both zotatifin, in Phase 2 expansion cohorts for the treatment of estrogen receptor positive breast cancer and KRAS non-small cell lung cancer as well as Phase 1 development for SARS-CoV-2, and tomivosertib, in a Phase 2b trial for the treatment of non-small cell lung cancer in combination with pembrolizumab, an established anti-immune checkpoint inhibitor used to treat various types of cancer.

CytomX Therapeutics, Inc. announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study.

CBRE|Raleigh is pleased to join affiliates of Apollo (NYSE: APO) and GeneSuites in announcing Catalyst BioCampus to the growing life sciences community in Holly Springs, NC.